Atalanta Therapeutics

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurological diseases by utilizing its proprietary RNA interference platform, di-siRNA, which for the first time enables RNA interference to be deployed as a therapeutic approach throughout the brain and spinal cord. The company's initial areas of therapeutic focus include Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease, alongside other ongoing preclinical research work in other CNS diseases.